What is MetascreenTM

MetascreenTM is a non-invasive, early detection test specially designed to screen more than 100 inherited metabolic disorders in newborns. MetascreenTMis a marketing trademark of Cordlife Group Limited, a Singapore Exchange Mainboard listed company. StemLife is a subsidiary of Cordlife Group Limited (Singapore). Cordlife Group is a consumer healthcare company that serves the needs of the mother and child.

The metabolic screening tests offered under the brand, MetascreenTM, will be conducted and analysed by Cordlife (Hong Kong) Ltd., a subsidiary of Cordlife Group committed to providing early and accurate detection of metabolic disorders in babies. Cordlife (Hong Kong) Ltd. has a quality management system in place to ensure maximum accuracy of screening results. Since beginning of 2015, Hong Kong Screening Centre has participated in and passed various external proficiency testing programs from College of American Pathologists and ERNDIM. Hong Kong Screening Centre also achieved the College of American Pathologists (CAP) accreditation in 2016.


Unlike blood specimen collection, collecting urine specimen is a non-invasive procedure which will not cause any harm or discomfort to your baby.


Where is your MetascreenTM technology from?

We use a gas-chromatography mass spectrometry (GC-MS) technology manufactured by Shimadzu, Japan. After processing the urine specimen through GC-MS, we analyse the GC-MS data using proprietary planar bioinformatics first developed by Japanese researchers. The planar bioinformatics makes use of multiple analytes (metabolites) from more than one biochemical (metabolic) pathway to identify a single metabolic disorder. This means that the results would be more reliable and accurate than traditional technology using mass tandem spectrometry (MS-MS) because MS-MS only uses about 1 or 2 analyte profiles for each disorder, and often, the same analyte profile is used for multiple disorders.